Eli Lilly 2013 Annual Report Download - page 14

Download and view the complete annual report

Please find page 14 of the 2013 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 160

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160

*Empagliozin
diabetes
*New insulin
glargine product
diabetes
Ramucirumab
solid tumors
Dulaglutide
diabetes
Baricitinib
rheumatoid
arthritis
Necitumumab
squamous NSCLC
Tabalumab
lupus
Solanezumab
Alzheimer’s
disease
Evacetrapib
high-risk vascular
disease
Edivoxetine
CNS disorder
Basal insulin
peglispro
diabetes
Ixekizumab
psoriasis/PsA
PCSK9 MAb
cardiovascular
disease
Blosozumab
osteoporosis
JAK2 inhibitor
cancer
TGF-ßR1 inhibitor
cancer
TGF-α/
epiregulin MAb
chronic kidney
disease
Myostatin MAb
disuse atrophy
c-Met inhibitor
cancer
CXCR4 peptide
antagonist
cancer
Olaratumab
cancer
Glucagon-R
antagonist
diabetes
c-Met MAb
cancer
FGF receptor
inhibitor
cancer
p38 MAP kinase
inhibitor
cancer
NOC-1 antagonist
depression
DKK-1 MAb
cancer
GSK3ß inhibitor
cancer
TGF-ß MAb
chronic kidney
disease
Florbenazine
imaging agent
Parkinson’s
disease
CDK 4/6
dual inhibitor
cancer
Hedgehog/SMO
antagonist
cancer
CGRP MAb
migraine
prevention
Chk1 inhibitor
cancer
Icrucumab
cancer
chronic kidney
disease
diabetes
CSF-1R MAb
cancer
p70S6/AKT
dual inhbitor
cancer
muscle
atrophy
Ferroportin MAb
anemia
diabetes
diabetes
Oxyntomodulin
peptide
diabetes
Hepcidin MAb
anemia
TGF-ßR2 MAb
cancer
mGlu2 agonist
CNS disorder
NOTCH inhibitor
cancer
VEGFR-3 MAb
cancer
N3pG-Aß MAb
Alzheimer’s
disease
P13 kinase/mTOR
dual inhibitor
cancer
Tau imaging
agent
Alzheimer’s
disease
diabetes
Pomaglumetad
CNS disorder
lupus
*Tanezumab
pain
Crohn’s disease
hypertension
mGlu2/3 agonist
chronic pain
EP4-R antagonist
osteoarthritic pain
Pan-Raf inhibitor
cancer
12
PIPELINE OF MOLECULES IN CLINICAL DEVELOPMENT
REGULATORY REVIEW
PHASE III
PHASE II
PHASE I
Information is current as of February 14, 2014. e search for new medicines is risky and uncertain, and there are no guarantees.
Remaining scientic and regulatory hurdles may cause pipeline compounds to be delaed or to fail to reach the market.
New Chemical Entity
New Biotech Entity
Diagnostic
*Commercial
collaboration
e Lilly pipeline currently in-
cludes 61 molecules in clinical
development. In 2004, we had
a total of seven assets in Phase
II and Phase III combined.
Today, we have 12 molecules in
Phase III or submission stage,
and 25 more in Phase II. In
2013, we saw positive Phase
III results for ve potential new
medicines, and we submitted
four—a record for Lilly—for
regulatory approval. We could
launch as many as three new
medicines this year, and we an-
ticipate additional regulatory
submissions this year as well.
Since our last annual report,
ten new molecules advanced
into Phase I testing, seven
advanced into Phase II testing,
and one, tanezumab, entered
Phase III in our portfolio,
as a result of our agreement
with Pzer to co-develop and
commercialize this molecule.
We terminated development of
17 molecules and discontinued
Phase III trials in depression
for edivoxetine, which is still
being investigated in Phase II
for multiple central nervous
system disorders. Additional
information and updates are
available on the Lilly Interac-
tive Pipeline at www.lilly.com.
In 2013, Elanco delivered
134 country level approvals.
is included important ad-
vancements in new geographies
and new areas of focus for
Elanco, including Western Eu-
rope, emerging markets, dairy,
diagnostics, and vaccines.
Other products augmented the
company’s companion animal
parasiticide franchise while
continued food animal innova-
tion assures our ability to meet
rapidly growing demand for
animal protein.